Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2013

View Archived Issues

Researchers uncover the mechanism behind malaria parasite sensitivity to spiroindolone-based drugs

Alemtuzumab treatment maintains efficacy in phase III extension study

Sernova receives Canadian funding for Sertolin technology

Pharmacodynamics of new rituximab biosimilar evaluated

Chinese researchers present new protein kinase inhibitors for cancer

Biovista and Dart Therapeutics enter collaboration

Researchers evaluate inflammatory and immune system biomarkers in chronic prostatitis

Omeros set to advance lead PDE10 inhibitor to phase II

Myriad Genetics to conduct HRD testing for PharmaMar

NICE recommends two treatments for lung infection in cystic fibrosis

Oncodesign to apply Nanocyclix technology to Sanofi kinase target

GNbAC-1 is safe and well tolerated in phase IIa trial

University of New Mexico to collaborate with Biosortia Pharmaceuticals

Soligenix cleared to begin phase II study of SGX-942

CureVac commences phase IIb trial of mRNA-based prostate cancer vaccine

A team of German researchers disclose novel antimalarial agents

Eisai obtains FDA approval for new formulation of AcipHex

Single nucleotide polymorphisms in MKL1 and CYP3A5 genes are associated with risk of CI-AKI

KU-046 improves cognitive function in vivo

Anaeropharma Science begins first-in-human trial of APS-001-F

Anthera Pharmaceuticals begins phase III CHABLIS-SC1 trial in lupus

Both primary endpoints met in pivotal study of Androxal

Novel phosphodiesterase inhibitors patented by Lundbeck

Japanese scientists design new ACC2 inhibitors

Novel Mnk1 inhibitors identified at Bayer

Invokana approved by the FDA for type 2 diabetes

NDA filed for hepatitis C candidate simeprevir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...